Meeting
2023 ASCO Annual Meeting
A powerful drug combination strategy targeting BRAF-mutant melanoma.
Authors
Luke Daniel Rothermel
University Hospitals, Seidman Cancer Center and Department of Surgery, Cleveland, OH
Luke Daniel Rothermel , Mehrdad Zarei , Alexander W Loftus , Jonathan J. Hue , Omid Hajihassani , Hallie J Graor , Jordan Michael Winter
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3152)
DOI
10.1200/JCO.2023.41.16_suppl.3152
Abstract #
3152
Poster Bd #
350
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2013 ASCO Annual Meeting
Relevance of MIA and S-100 to monitor BRAF inhibitor (iBRAF) therapy in metastatic melanoma patients.
First Author: Miguel F. Sanmamed
Poster
2016 ASCO Annual Meeting
Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.
First Author: Shiraj Sen
Poster
2016 ASCO Annual Meeting
Influence of melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of patients with metastatic melanoma harboring the BRAF mutation and treated with BRAF inhibitors.
First Author: Sabino Strippoli